InMed Pharmaceuticals (INM) Receivables (2020 - 2025)
InMed Pharmaceuticals (INM) reported Receivables of $182967.0 for Q4 2025, down 30.32% on a YoY basis from $262569.0 in Q4 2024, and down 46.73% quarter-over-quarter from $343469.0 in Q3 2025.
InMed Pharmaceuticals (INM) Receivables (2020 - 2025) Analysis & Trends
InMed Pharmaceuticals has reported Receivables for 6 years, with the latest figure at $182967.0 in Q4 2025.
- For the quarter ending Q4 2025, Receivables fell 30.32% year-over-year to $182967.0; the trailing twelve-month figure through Dec 2025 stood at $182967.0 (down 30.32% YoY), and the FY2025 full-year result was $2.0 million, up 5526.41% from the prior year.
- Receivables for Q4 2025 stood at $182967.0, down from $343469.0 in the prior quarter.
- The five-year high for Receivables was $465104.0 in Q2 2025, with the low at $11919.0 in Q2 2021.
- Historically, Receivables has averaged $147671.6 across 5 years, with a median of $76100.5 in 2022.
- Annual changes were most pronounced in 2021 — Receivables tumbled 73.71% — and 2025, when it surged 1240.36%.
- InMed Pharmaceuticals' Receivables stood at $50304.0 in 2021, then soared by 62.31% to $81647.0 in 2022, then fell by 18.21% to $66775.0 in 2023, then surged by 293.21% to $262569.0 in 2024, then plunged by 30.32% to $182967.0 in 2025.
- The last three Receivables figures came in at $182967.0 (Q4 2025), $343469.0 (Q3 2025), and $465104.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 3.39 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 1.51 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 312.00 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 31.29 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 768.10 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 1.15 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 407.63 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 355.67 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 149.62 Mn |
| 10 | InMed Pharmaceuticals | 6.00 Mn | 756,271.05 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 182,967.00 |
| Sep 30, 2025 | 343,469.00 |
| Jun 30, 2025 | 465,104.00 |
| Mar 31, 2025 | 367,813.00 |
| Dec 31, 2024 | 262,569.00 |
| Sep 30, 2024 | 284,695.00 |
| Jun 30, 2024 | 34,700.00 |
| Mar 31, 2024 | 207,681.00 |
| Dec 31, 2023 | 66,775.00 |
| Sep 30, 2023 | 165,850.00 |
| Jun 30, 2023 | 66,775.00 |
| Mar 31, 2023 | 170,299.00 |
| Dec 31, 2022 | 81,647.00 |
| Sep 30, 2022 | 15,169.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | 70,554.00 |
| Dec 31, 2021 | 50,304.00 |
| Sep 30, 2021 | 14,842.00 |
| Jun 30, 2021 | 11,919.00 |
| Mar 31, 2021 | 70,300.00 |